Welcome to this month's ADVOCATE BRIEF
September rewarded everyone with a seat at the table. Patients need not apply
Four deals moved in the same month, and patients signed none of them. Twenty-six drugmakers struck private White House agreements that may exempt their medicines from Medicare's new price models. Phase two of the 100 percent drug tariffs took effect on September 29 with an exit door reserved for companies that signed those deals. Medicare Advantage insurers cut thousands of plans for 2027 and raised what seniors pay. Hospitals and insurers pointed artificial intelligence at each other and billed the cost of the fight to the system.
A Lancet cohort study found that exempting the deal-making companies would erase 71.3 percent of the projected Medicare savings from most-favored-nation pricing. The Wall Street Journal reported that 92 percent of providers now encourage or require payment before care, up from 81 percent a year earlier. Healthcare Dive found average maximum out-of-pocket limits in Medicare Advantage rising 10 percent for 2027 and Part D deductibles rising 30 percent, two weeks before open enrollment starts on October 15.
I have sat in enough negotiating rooms to know who those rooms leave out, and September left out the same person every time. Each side deal resolved into the two questions a patient actually asks, which are whether the drug arrives and what it costs, and nobody at the table answered for the person asking.
Four storylines ran through September, and they share one mechanism. Institutions cut deals with each other, and the patient absorbs the terms through prepayment, paperwork, and algorithms. Organizations that want a different outcome need to sit in those rooms before the fourth quarter locks 2027 budgets, not after the open enrollment letters arrive.
Sally Nix published her Blue Cross NC denial letter, Mark Cuban shared it, and the CEO's office called within days. Her argument runs structural: the insurer folded the trigeminal nerve block code into a migraine injection policy in 2020, and annual policy reviews trail the clinical evidence. No patient should need a billionaire's feed to earn a fair review.
KFF Health News reported on a young man with a rare brain tumor whose PBM denied Lynparza as "not approved for the diagnosis provided," leaving an 8,700 dollar monthly bill, and an independent nonspecialist reviewer backed the denial. AstraZeneca shipped the drug the day after his mother posted publicly and tagged the company. Rare cancers account for roughly a quarter of US cancers, and label-bound coverage rules leave those families to fight alone.
STAT reports Novo Nordisk logged 7 million prescriptions for its Wegovy pill this year with 90 percent of sales running direct to consumer, and the company now talks about customers rather than patients. The STOP Obesity Alliance and clinicians warn that retail positioning undercuts years of advocacy for obesity coverage parity, and cash prices of 400 to 450 dollars a month turn access into a question of means.
University of Colorado Denver sociologist Jennifer Reich has spent two decades talking with parents who decline vaccines, and she told STAT that many started out pro-vaccine before rushed pediatric visits pushed them toward peer groups that listened.
A DIA and Tufts CSDD benchmark and a Bayer Oncology case study on patient advisors reach one finding. Most sponsors buy the easy version of engagement, stipends and incentives, while few run patient steering committees or bring advisors in before protocols lock.
Engagement that works only under public pressure fails every patient who never goes viral. Trust gets built in the quiet years and spent in a single news cycle.
STAT obtained documents showing CMS rushed its WISeR AI prior authorization pilot, and vendor Innovaccer warned it would go live without full functionality and auto-approved every request to avoid a backlog. Vendors earn 25 percent of the value of a denied claim, and an HHS OIG review of a Medicare Advantage program found 82 percent of patients never appeal.
The New York Times reports a Blue Cross Blue Shield Association study found hospitals using AI coding tools added secondary diagnoses without evidence of different treatment, earning nearly 12,000 dollars more per case and adding close to 1 billion dollars in costs over two years. Insurers answer with their own AI to scan charts for denials, and patients sit in the middle of the bots fighting the bots.
CMS will expand its ACCESS chronic care model with new condition tracks in spring 2027, and 17 health plans covering 165 million people committed to aligned payment.
An FDA advisory panel voted 7 to 2 that the benefits of Grail's Galleri multi-cancer test outweigh its risks, but only 6 to 4 on effectiveness, after an FDA official told the panel that a third to half of positive results come back false. Patient groups need plain-language guidance ready.
FDA approved FAYUVI, the first treatment for Sanfilippo syndrome type A, after the asset nearly died for lack of funding. Cure Sanfilippo Foundation and National MPS Society leaders co-authored the approval statement.
Every one of these tools shifts work onto patients unless someone builds patient review in from the first design meeting.
September 2026 proved that institutions now decide access in side agreements, fee structures, and plan landscapes rather than in statutes. Twenty-six private pharma deals could erase most of Medicare's projected MFN savings. Ninety-two percent of providers now want payment before care. Seniors open their 2027 Medicare Advantage letters this month to find higher out-of-pocket limits and steeper Part D deductibles.
Pharma and biotech teams that connect advocacy insight to execution before 2027 budgets lock will lead the next two quarters. Patient advocacy organizations that file comments, hand member stories to investigators, and build paperwork playbooks before January 1 will decide what their communities can reach next year.
Originally published in The Archo Advocate Brief.
